Compare PAX & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PAX | OGN |
|---|---|---|
| Founded | 1988 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2020 | 2020 |
| Metric | PAX | OGN |
|---|---|---|
| Price | $11.49 | $13.77 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 5 |
| Target Price | ★ $15.00 | $11.25 |
| AVG Volume (30 Days) | 1.1M | ★ 2.0M |
| Earning Date | 11-03-2026 | 11-09-2026 |
| Dividend Yield | ★ 5.59% | 0.58% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.95 |
| Revenue | N/A | ★ $6,216,000,000.00 |
| Revenue This Year | $13.76 | N/A |
| Revenue Next Year | $10.10 | $2.51 |
| P/E Ratio | $25.65 | ★ $14.49 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.89 | $5.69 |
| 52 Week High | $17.80 | $13.83 |
| Indicator | PAX | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 61.63 | 56.76 |
| Support Level | $11.04 | $13.46 |
| Resistance Level | $11.62 | $13.77 |
| Average True Range (ATR) | 0.28 | 0.04 |
| MACD | 0.17 | 0.00 |
| Stochastic Oscillator | 79.80 | 50.00 |
Patria Investments Ltd is an alternative asset management firm specializing in resilient sectors across select regions. It seeks to provide world-wide and Latin American investors with attractive investment products that allows portfolio diversification and consistent returns. The group promotes inclusive and sustainable development in the Asset Classes: Private Equity, Private Equity Solutions, Credit, Real Estate, Infrastructure, and Public Equities Main sectors: Agribusiness, Power & Energy, Healthcare, Logistics & Transportations, Food & Beverage and Digital & Tech Services Investment Regions.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.